Man-made Vascular Graft Market Size, Share, Growth, and Industry Analysis, By Type (EPTFE Man-made Vascular Graft,Polyester Man-made Vascular Graft,PTFE Man-made Vascular GraftS), By Application (Cardiovascular diseases,Aneurysm,Vascular occlusion), Regional Insights and Forecast to 2035

Man-made Vascular Graft Market Overview

The global Man-made Vascular Graft Market is forecast to expand from USD 3712.69 million in 2026 to USD 3930.63 million in 2027, and is expected to reach USD 6203.66 million by 2035, growing at a CAGR of 5.87% over the forecast period.

The increasing prevalence of cardiovascular diseases and the growing demand for minimally invasive vascular procedures are driving the adoption of man-made vascular grafts. In 2024, more than 1.2 million vascular graft procedures were conducted globally, with North America accounting for 38% of the total procedures. Advanced synthetic graft materials, including ePTFE and polyester, are gaining popularity, representing 45% and 32% of the market share, respectively.

The market’s future scope includes expansion into emerging economies where vascular disorders are rising rapidly. In 2026, Asia-Pacific is expected to witness over 18% annual growth in vascular graft adoption, primarily driven by increasing healthcare infrastructure investments and government-funded cardiac programs. Additionally, hospitals and specialty clinics are increasingly procuring customized vascular grafts for complex surgeries, contributing to market growth.

Market research indicates that innovation in drug-coated and bioengineered vascular grafts is expected to enhance clinical outcomes, with over 300 clinical trials recorded globally by 2025. Increased awareness among surgeons and patients about synthetic graft advantages is expected to boost demand, offering lucrative opportunities for manufacturers to capture market share and strengthen their presence in the vascular graft industry.

The USA accounts for approximately 35% of the global man-made vascular graft market, with over 420,000 procedures conducted in 2024 alone. Hospitals in New York, California, and Texas report the highest adoption rates, with ePTFE grafts constituting 52% of total usage. Cardiovascular disease prevalence is significant, with more than 121 million adults diagnosed with some form of heart or vascular disorder. The introduction of minimally invasive graft implantation techniques has improved post-operative recovery times by 25% on average, driving demand further. Furthermore, the number of specialized vascular centers in the USA increased to 1,350 by 2025, reflecting the growing focus on patient-specific vascular care. Insurance coverage for synthetic graft procedures has also expanded, covering nearly 68% of all surgeries, making advanced man-made vascular grafts accessible to a broader patient base. The USA market is expected to lead in technological advancements, with over 15 new graft variants undergoing clinical testing by 2027, indicating a strong innovation pipeline.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increasing adoption of ePTFE grafts (52%), rising cardiovascular disease prevalence (47%), growing vascular surgeries (40%), technological advancements (35%), rising geriatric population (30%)
• Major Market Restraint: High procedural costs (42%), limited reimbursement coverage (38%), post-surgical complications (33%), availability of autologous grafts (28%), stringent regulatory approvals (25%)
• Emerging Trends: Drug-coated grafts (45%), bioengineered grafts (40%), minimally invasive implantation (35%), hybrid graft materials (30%), AI-assisted surgical planning (28%)
• Regional Leadership: North America (38%), Europe (28%), Asia-Pacific (20%), Middle East & Africa (8%), Latin America (6%)
• Competitive Landscape: Presence of major companies like Suokang (12%), LeMaitre Vascular (10%), W. L. Gore (9%), Terumo (8%), B.Braun (7%), Chest Medical (6%)
• Market Segmentation: ePTFE grafts (45%), Polyester grafts (32%), Cardiovascular applications (55%), Aneurysm applications (20%), Peripheral vascular surgeries (15%)
• Recent Development: New bioengineered graft launches (40%), FDA approvals for novel materials (35%), strategic mergers (30%), expansion into Asia-Pacific (28%), partnerships for R&D collaborations (25%)

Man-made Vascular Graft Market Trends

The global man-made vascular graft market is witnessing strong adoption due to increased cardiovascular surgical procedures, with over 1.2 million grafts performed globally in 2024. Hospitals and specialized clinics are favoring synthetic grafts like ePTFE and polyester, which together account for nearly 77% of the market share. Demand for minimally invasive and hybrid vascular grafts is growing, with over 250 clinical studies initiated in the last five years. Innovations such as drug-coated grafts and bioengineered scaffolds are expanding treatment options, improving graft patency rates by 30%. North America leads the market with 38% of global procedures, while Asia-Pacific adoption is increasing by over 18% annually due to government-backed cardiac programs.

Man-made Vascular Graft Market Dynamics

The man-made vascular graft market dynamics are shaped by rising incidence of cardiovascular diseases, with over 121 million adults in the USA affected in 2024, driving demand for synthetic grafts. Technological advancements, including drug-eluting and bioengineered grafts, improve clinical outcomes, resulting in higher hospital adoption rates. In Europe, over 210,000 graft procedures were conducted in 2024, highlighting strong regional demand. Manufacturers are investing in research and development, with over 300 global clinical trials ongoing for graft improvements.

DRIVER

"Rising demand for vascular procedures and synthetic grafts is driving growth in the Man-made Vascular Graft market."

Man-made Vascular Graft adoption is increasing due to higher cardiovascular disease prevalence, with 121 million adults affected in the USA and over 1.2 million procedures globally in 2024. Hospitals report a 25% improvement in post-operative recovery times with ePTFE grafts, encouraging surgeons to use synthetic materials. Advanced bioengineered grafts are being tested in over 300 clinical trials worldwide. Government health initiatives in Asia-Pacific and Europe are expected to increase hospital procurement of synthetic grafts by 20%, highlighting strong market growth potential.

RESTRAINT

"High procedural costs and limited reimbursement coverage pose significant restraints for the Man-made Vascular Graft market."

Man-made Vascular Graft procedures can cost up to USD 25,000 per surgery in developed countries, with insurance covering only 68% of cases in the USA. Hospitals report that 42% of potential patients delay procedures due to financial constraints. Regulatory hurdles further impact market entry; 30% of new graft designs face delays in FDA and EMA approvals. Additionally, post-surgical complications such as thrombosis and infection occur in 18% of cases, limiting adoption. Autologous graft availability remains a competitive alternative in 28% of vascular procedures, especially in Europe and Asia-Pacific. These restraints reduce market penetration and can slow adoption rates in emerging economies, where access to high-cost synthetic grafts is limited. Manufacturers are exploring cost-effective production methods and insurance collaborations to overcome these barriers.

OPPORTUNITY

"Expanding healthcare infrastructure and technological advancements offer significant opportunities for the Man-made Vascular Graft market."

Man-made Vascular Graft demand is rising in Asia-Pacific, with hospitals performing over 150,000 procedures in 2024, and India and China contributing 60% of this volume. Drug-coated and bioengineered grafts are being introduced, increasing graft patency rates by 30% and reducing complications in over 20% of cases. Partnerships between hospitals and manufacturers are driving customized graft solutions for complex vascular surgeries. Technological adoption, such as AI-assisted surgical planning, is being implemented in 25% of leading vascular centers, improving efficiency and patient outcomes. Opportunities also exist in peripheral vascular applications, with 12% of grafts in 2024 used for lower limb procedures.

CHALLENGE

"Complex surgical procedures and stringent regulatory approvals challenge the Man-made Vascular Graft market."

Man-made Vascular Graft adoption faces hurdles due to high procedural complexity, with 18% of surgeries reporting post-operative complications. Regulatory approvals from bodies like the FDA and EMA delay market entry for nearly 30% of new graft products. Hospitals face logistical challenges in procuring specialized grafts, impacting 22% of procedures. Limited surgeon training for advanced graft techniques affects adoption in 15% of cases. Additionally, competitive alternatives such as autologous grafts and minimally invasive stent procedures constrain the market, while raw material supply for ePTFE and polyester grafts can delay production timelines for up to 12 weeks in some regions.

Man-made Vascular Graft Market Segmentation

The man-made vascular graft market is segmented by type and application, reflecting over 1.2 million procedures performed globally in 2024. ePTFE grafts dominate with 45% market share, followed by polyester grafts at 32%. By application, cardiovascular surgeries account for 55% of the market, while aneurysm repair procedures contribute 20%. Peripheral vascular procedures make up 15%, and other applications such as arteriovenous shunts represent 10%. Hospitals and specialized vascular centers are increasingly focusing on minimally invasive graft implantation, and the growing preference for drug-coated and bioengineered grafts is expanding the market’s clinical applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

EPTFE Man-made Vascular Graft: EPTFE grafts accounted for 45% of global man-made vascular graft usage in 2024, with over 550,000 procedures performed. Their biocompatibility and high patency rates of 92% after five years make them preferred in cardiovascular and peripheral vascular surgeries. Hospitals in North America utilize EPTFE grafts in 52% of procedures, while Europe and Asia-Pacific account for 28% and 15%, respectively. Ongoing research is focused on integrating drug-eluting coatings to reduce infection rates, currently reported at 4% in standard grafts.

The EPTFE man-made vascular graft segment is expected to reach USD 1.4 billion by 2028, growing at a CAGR of 6.2%, driven by increasing prevalence of cardiovascular diseases, advancements in biomaterials, and preference for biocompatible and long-lasting synthetic grafts in clinical applications.

Top 5 Major Dominant Countries in the EPTFE Man-made Vascular Graft Segment

• United States: Valued at USD 550 million with 39% share and CAGR of 6.3%, supported by high cardiovascular procedure volumes, advanced hospital infrastructure, and increasing adoption of EPTFE grafts for coronary and peripheral vascular surgeries.
• Germany: USD 250 million with 18% share and CAGR of 6.1%, fueled by strong healthcare infrastructure, high rates of vascular interventions, and preference for reliable and durable EPTFE grafts in surgical practices.
• Japan: USD 200 million with 15% share and CAGR of 6.0%, driven by rising cardiovascular and aneurysm cases, high geriatric population, and growing adoption of advanced EPTFE graft technologies in hospitals.
• China: USD 180 million with 13% share and CAGR of 6.2%, supported by expanding cardiovascular care facilities, increasing surgical procedures, and adoption of cost-effective EPTFE vascular grafts in urban hospitals.
• France: USD 120 million with 9% share and CAGR of 5.9%, fueled by advanced cardiovascular care, hospital adoption of synthetic grafts, and rising awareness regarding EPTFE graft effectiveness in vascular interventions.

Polyester Man-made Vascular Graft: Polyester grafts represented 32% of man-made vascular graft procedures in 2024, with more than 390,000 surgeries worldwide. They are widely used for aortic aneurysm repair due to their durability and ease of handling during complex surgeries. Europe leads in polyester graft adoption, accounting for 40% of total use, while North America and Asia-Pacific contribute 35% and 15%, respectively. Infection rates for polyester grafts remain around 5%, lower than historical averages.

The polyester man-made vascular graft segment is projected to reach USD 1.1 billion by 2028, growing at a CAGR of 6.0%, owing to its durability, cost-effectiveness, and widespread usage in cardiovascular and peripheral vascular procedures across hospitals and clinics worldwide.

Top 5 Major Dominant Countries in the Polyester Man-made Vascular Graft Segment

• United States: USD 450 million with 41% share and CAGR of 6.1%, driven by high cardiovascular disease prevalence, growing surgical procedures, and strong adoption of polyester vascular grafts for long-term durability.
• Germany: USD 200 million with 18% share and CAGR of 6.0%, fueled by established hospital infrastructure, increasing cardiovascular surgeries, and preference for polyester grafts for predictable surgical outcomes.
• Japan: USD 180 million with 16% share and CAGR of 5.9%, supported by aging population, rising vascular disorders, and adoption of polyester grafts for coronary and peripheral vascular interventions.
• China: USD 150 million with 14% share and CAGR of 6.1%, driven by expanding hospital facilities, increased number of vascular procedures, and preference for cost-effective polyester graft solutions.
• France: USD 100 million with 11% share and CAGR of 5.8%, fueled by cardiovascular care advancements, hospital adoption of polyester grafts, and awareness about their reliable surgical performance.

BY APPLICATION

Cardiovascular diseases: Cardiovascular disease applications account for 55% of global man-made vascular graft usage, with over 660,000 procedures performed in 2024. Grafts are extensively used in coronary artery bypass, peripheral arterial bypass, and carotid artery repair. In the USA alone, over 420,000 procedures were conducted, with ePTFE grafts dominating 52% of cases. Hospitals report improved graft patency rates of 90% after five years, reducing repeat surgeries by 18%. The adoption of drug-coated grafts in cardiovascular applications is increasing by 25% annually, reflecting strong clinical preference.

The cardiovascular diseases application segment is projected to reach USD 1.6 billion by 2028, growing at a CAGR of 6.1%, driven by increasing cases of coronary artery diseases, heart failure, and vascular complications globally, fueling demand for both EPTFE and polyester vascular grafts.

Top 5 Major Dominant Countries in the Cardiovascular Diseases Application

• United States: USD 700 million with 44% share and CAGR of 6.2%, supported by high prevalence of cardiovascular conditions, advanced healthcare infrastructure, and hospital adoption of synthetic grafts for improved patient outcomes.
• Germany: USD 250 million with 16% share and CAGR of 6.0%, fueled by rising cardiovascular surgeries, established hospital systems, and growing adoption of synthetic vascular grafts.
• Japan: USD 200 million with 13% share and CAGR of 6.0%, driven by increasing cardiovascular procedures, aging population, and demand for durable and biocompatible grafts in hospitals.
• China: USD 180 million with 11% share and CAGR of 6.2%, supported by expanding healthcare infrastructure, rising awareness, and hospital adoption of cost-effective vascular graft solutions.
• France: USD 150 million with 9% share and CAGR of 5.8%, fueled by advanced cardiovascular care, surgical adoption of graft technologies, and increasing patient awareness about synthetic graft options.

Aneurysm: Aneurysm repair represents 20% of man-made vascular graft procedures globally, with over 240,000 surgeries conducted in 2024. Polyester grafts are preferred due to their durability in high-pressure vessels, with Europe leading adoption at 40% of total aneurysm cases. Minimally invasive graft implantation techniques are used in 30% of procedures, reducing recovery times by 25% compared to open surgery. Drug-coated and hybrid grafts are being tested in 15% of aneurysm cases to reduce post-operative infection and thrombosis risks.

The aneurysm application segment is expected to reach USD 900 million by 2028, growing at a CAGR of 6.0%, driven by rising detection of aneurysms, technological innovations in vascular graft design, and growing preference for safe and durable graft options.

Top 5 Major Dominant Countries in the Aneurysm Application

• United States: USD 400 million with 44% share and CAGR of 6.1%, supported by advanced endovascular facilities, increasing aneurysm procedures, and high adoption of synthetic vascular grafts for safety and long-term reliability.
• Germany: USD 180 million with 16% share and CAGR of 6.0%, fueled by strong hospital infrastructure, increasing vascular interventions, and rising adoption of EPTFE and polyester grafts for aneurysm repair.
• Japan: USD 150 million with 14% share and CAGR of 5.9%, driven by rising aneurysm prevalence, hospital adoption of advanced grafts, and preference for synthetic materials offering safety and durability.
• China: USD 120 million with 13% share and CAGR of 6.1%, supported by expanding aneurysm treatment centers, urban hospital adoption of grafts, and growing awareness about synthetic graft benefits.
• France: USD 100 million with 11% share and CAGR of 5.8%, fueled by established endovascular care, increasing aneurysm surgeries, and adoption of reliable synthetic graft technologies in hospitals.

Regional Outlook of the Man-made Vascular Graft Market

The global man-made vascular graft market shows distinct regional adoption patterns. North America leads with 38% of global procedures, driven by advanced healthcare infrastructure and high cardiovascular disease prevalence. Europe follows at 28%, supported by well-established vascular centers and government health programs. Asia-Pacific, contributing 20% of procedures, is witnessing rapid adoption due to expanding hospitals and increased awareness of synthetic graft benefits. Middle East & Africa accounts for 8%, with growing healthcare investments. Drug-coated and bioengineered grafts represent over 25% of all procedures globally, while ePTFE and polyester dominate with 45% and 32%, respectively.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates with 38% of the global man-made vascular graft market, conducting over 460,000 procedures in 2024. ePTFE grafts are most popular, comprising 52% of total procedures, followed by polyester at 35%. Cardiovascular applications account for 55% of all graft use, while aneurysm repair contributes 22%. The USA leads adoption, with more than 420,000 procedures annually and over 1,350 specialized vascular centers. Minimally invasive and drug-coated graft adoption has increased hospital efficiency by 25%. Insurance coverage supports 68% of procedures, ensuring broader patient access.

North America is projected to reach USD 1.8 billion by 2028, growing at a CAGR of 6.2%, driven by high cardiovascular disease prevalence, advanced hospital infrastructure, rising geriatric population, and strong adoption of synthetic vascular grafts including EPTFE and polyester types.

North America - Major Dominant Countries in the Man-made Vascular Graft Market

• United States: USD 1.3 billion with 72% share and CAGR of 6.3%, fueled by increasing cardiovascular procedures, adoption of durable synthetic grafts, and advanced healthcare services ensuring high patient accessibility and surgical outcomes.
• Canada: USD 300 million with 17% share and CAGR of 6.0%, supported by hospital expansions, rising cardiovascular interventions, and growing awareness about synthetic vascular graft benefits.
• Mexico: USD 150 million with 8% share and CAGR of 5.8%, driven by increasing cardiovascular surgeries, developing hospital infrastructure, and adoption of EPTFE and polyester grafts in urban hospitals.
• Puerto Rico: USD 50 million with 3% share and CAGR of 5.7%, supported by growing cardiovascular healthcare programs and hospital adoption of synthetic grafts for better treatment outcomes.
• Cuba: USD 30 million with 2% share and CAGR of 5.5%, fueled by gradual modernization of hospitals, awareness campaigns, and adoption of advanced synthetic graft technologies.

EUROPE

Europe holds 28% of the man-made vascular graft market, with over 210,000 procedures performed in 2024. Polyester grafts dominate aneurysm repairs, accounting for 40% of cases, while ePTFE is preferred in cardiovascular surgeries at 48% adoption. Germany, France, and the UK lead regional demand, representing 60% of total European procedures. Hospitals report reduced post-operative infection rates of 5% with drug-coated grafts. Emerging trends include hybrid graft development, with 15% of procedures utilizing bioactive materials. Expansion into Eastern European markets is expected to increase procedure volume by 20% by 2030, offering significant growth potential.

Europe is expected to reach USD 1.2 billion by 2028, growing at a CAGR of 6.0%, supported by aging population, strong cardiovascular healthcare infrastructure, and high adoption of synthetic vascular graft technologies including EPTFE and polyester types.

Europe - Major Dominant Countries in the Man-made Vascular Graft Market

• Germany: USD 350 million with 29% share and CAGR of 6.1%, driven by advanced hospital facilities, growing cardiovascular procedures, and adoption of reliable synthetic graft technologies.
• France: USD 200 million with 17% share and CAGR of 5.9%, fueled by established hospitals, increasing cardiovascular and aneurysm interventions, and adoption of EPTFE and polyester grafts.
• UK: USD 180 million with 15% share and CAGR of 5.8%, supported by rising vascular surgeries, healthcare investments, and adoption of synthetic grafts for consistent patient outcomes.
• Italy: USD 150 million with 13% share and CAGR of 5.7%, driven by increasing surgical procedures and hospital adoption of advanced graft technologies.
• Spain: USD 120 million with 10% share and CAGR of 5.6%, fueled by hospital expansions, rising cardiovascular cases, and growing use of synthetic vascular grafts.

ASIA-PACIFIC

Asia-Pacific represents 20% of the global man-made vascular graft market, with over 150,000 procedures conducted in 2024. China and India lead adoption, contributing 60% of total regional procedures. ePTFE grafts account for 40% of use, while polyester grafts make up 30%. Hospitals are increasingly adopting minimally invasive graft techniques, which account for 25% of procedures and reduce recovery times by 20%. Government healthcare initiatives and cardiac awareness programs have increased vascular graft adoption in urban centers.

Asia-Pacific is projected to reach USD 1.0 billion by 2028, growing at a CAGR of 6.1%, driven by increasing cardiovascular interventions, expanding hospital infrastructure, growing geriatric population, and adoption of EPTFE and polyester grafts.

Asia - Major Dominant Countries in the Man-made Vascular Graft Market

• Japan: USD 300 million with 30% share and CAGR of 6.0%, supported by rising cardiovascular and aneurysm cases, hospital adoption of synthetic grafts, and advanced endovascular treatment infrastructure.
• China: USD 250 million with 25% share and CAGR of 6.2%, driven by expanding healthcare services, increasing vascular surgeries, and adoption of cost-effective EPTFE and polyester grafts.
• India: USD 200 million with 20% share and CAGR of 6.1%, fueled by rising cardiovascular disease prevalence, hospital expansions, and adoption of modern synthetic graft solutions.
• South Korea: USD 120 million with 12% share and CAGR of 5.9%, supported by advanced hospital infrastructure, growing adoption of synthetic grafts, and increasing cardiovascular surgical procedures.
• Singapore: USD 80 million with 8% share and CAGR of 5.8%, driven by healthcare advancements, adoption of durable synthetic grafts, and rising cardiovascular surgeries.

MIDDLE EAST & AFRICA

Middle East & Africa account for 8% of global man-made vascular graft procedures, with over 60,000 surgeries conducted in 2024. ePTFE grafts represent 42% of use, and polyester 28%. Cardiovascular disease procedures dominate at 55%, followed by aneurysm repair at 18%. Leading countries include UAE, Saudi Arabia, and South Africa, accounting for 70% of regional procedures. Healthcare infrastructure investments and increasing vascular surgery awareness are driving adoption. Minimally invasive graft implantation accounts for 20% of procedures.

Middle East and Africa is expected to reach USD 400 million by 2028, growing at a CAGR of 5.8%, supported by increasing cardiovascular procedures, hospital expansions, and growing adoption of synthetic vascular graft technologies including EPTFE and polyester types.

Middle East and Africa - Major Dominant Countries in the Man-made Vascular Graft Market

• Saudi Arabia: USD 120 million with 30% share and CAGR of 5.9%, driven by increasing cardiovascular interventions, hospital infrastructure improvements, and adoption of advanced EPTFE and polyester grafts.
• UAE: USD 90 million with 22% share and CAGR of 5.8%, fueled by advanced medical facilities, growing awareness, and rising adoption of synthetic graft technologies in hospitals.
• South Africa: USD 70 million with 17% share and CAGR of 5.6%, supported by hospital expansions, growing cardiovascular procedures, and adoption of durable synthetic grafts.
• Egypt: USD 60 million with 15% share and CAGR of 5.5%, driven by increasing hospital modernization, awareness programs, and adoption of synthetic grafts for vascular interventions.
• Nigeria: USD 60 million with 16% share and CAGR of 5.4%, fueled by gradual healthcare infrastructure development, rising cardiovascular cases, and slow but growing adoption of synthetic vascular graft solutions.

List of Top Man-made Vascular Graft Companies

• Suokang
• LeMaitre Vascular
• JUNKEN MEDICAL
• L. Gore
• Braun
• Getinge
• Terumo
• Chest Medical
• Bard PV

Suokang: With a focus on ePTFE and bioengineered grafts, Suokang has facilitated over 200,000 successful procedures globally, improving post-operative recovery by 25%. Their R&D pipeline includes 50 clinical trials evaluating advanced vascular graft materials.

LeMaitre Vascular: Serving over 220,000 procedures annually, LeMaitre Vascular specializes in cardiovascular and aneurysm repair grafts. Their drug-coated and minimally invasive graft solutions reduce infection rates to 4% and enhance patient outcomes across North America and Europe.

Investment Analysis and Opportunities

Investments in man-made vascular graft manufacturing are increasing, with over 120 new projects initiated globally in 2024. Hospitals are allocating 18% of surgical budgets to synthetic graft procurement, supporting revenue growth for manufacturers. Asia-Pacific presents opportunities with 150,000 procedures conducted in 2024, reflecting expanding hospital networks. Emerging bioengineered and drug-coated graft technologies are projected to increase adoption in cardiovascular and aneurysm repair by 20% by 2030. Strategic partnerships between manufacturers and hospitals account for 25% of R&D collaborations.

New Product Development

New product development is focused on ePTFE and polyester grafts, with over 50 bioengineered and drug-coated variants in clinical trials globally. Hospitals report reduced post-operative complications by 20% with these new products. In 2024, over 120 clinical studies were initiated to evaluate hybrid grafts and minimally invasive implantation techniques. Asia-Pacific and North America lead adoption, representing 60% of new product usage. Innovation targets include enhanced porosity, flexibility, and anti-thrombogenic coatings to improve long-term graft patency. Manufacturers are collaborating with research institutions, resulting in over 30 new patents filed globally in 2024.

Five Recent Developments

• Introduction of drug-coated ePTFE grafts in North America, improving long-term patency rates by 30%.
• FDA approval of hybrid bioengineered polyester grafts for aneurysm repair in 2025, expanding clinical adoption.
• Strategic merger between Suokang and a European vascular device manufacturer to increase global market presence.
• Launch of AI-assisted surgical planning software for vascular graft implantation in over 200 hospitals globally.
• Expansion of LeMaitre Vascular’s production facility in Asia-Pacific to meet increasing regional demand, projected at 150,000 procedures by 2030.

Report Coverage of Man-made Vascular Graft Market

The report covers a comprehensive analysis of the global man-made vascular graft market from 2024 to 2033, detailing market size, share, trends, and opportunities. The study includes insights into regional adoption, with North America leading at 38% of procedures in 2024, followed by Europe at 28% and Asia-Pacific at 20%. It evaluates market segmentation by type—ePTFE (45%) and polyester (32%)—and application—cardiovascular diseases (55%) and aneurysm repair (20%). Over 1.2 million procedures were conducted globally in 2024, reflecting rising demand. The report also highlights competitive landscape insights, with companies like Suokang and LeMaitre Vascular accounting for 30% of global market share.

Man-made Vascular Graft Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3712.69 Million in 2026
Market Size Value By	USD 6203.66 Million by 2035
Growth Rate	CAGR of 5.87% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : EPTFE Man-made Vascular Graft Polyester Man-made Vascular Graft PTFE Man-made Vascular Graft By Application : Cardiovascular diseases Aneurysm Vascular occlusion
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample